Who makes [18F]MK-6240, ~160 MBq?

[18F]MK-6240, ~160 MBq is developed by Merck Sharp & Dohme LLC.

What development phase is [18F]MK-6240, ~160 MBq in?

[18F]MK-6240, ~160 MBq is in Phase 1.

Last reviewed 2026-05-14 · How we verify

[18F]MK-6240, ~160 MBq

Merck Sharp & Dohme LLC · Phase 1 active Small molecule

At a glance

Generic name	[18F]MK-6240, ~160 MBq
Sponsor	Merck Sharp & Dohme LLC
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

[18F]MK-6240, ~160 MBq CI brief — competitive landscape report
[18F]MK-6240, ~160 MBq updates RSS · CI watch RSS
Merck Sharp & Dohme LLC portfolio CI